The IPSS-R is a system used to assess risk and predict clinical outcomes in MDS. A revised version of the IPSS-R classification now includes 5 (instead of 3) cytogenetic prognostic factors:1
Based on these and other prognostic factors, the IPSS-R stratifies patients into risk categories by score:
|Blasts in bone marrow||≤2%||0|
|Cell DNA changes
The IPSS-R scoring system is used only at the time of MDS diagnosis as it does not take into account the impact of transfusions on the prognosis of MDS patients.2Learn about a dynamic risk stratification system >
All fields are required.
You are now leaving the IronHealthalliance.com website by opening an external website independently operated and not managed by Novartis. Novartis assumes no responsibility for the site you are about to visit. If you do not wish to leave this site, click "Cancel." Otherwise, click "Continue".